Literature DB >> 19060342

Prevalence and significance of white-coat hypertension and masked hypertension in type 2 diabetics.

C M Ng1, S F Yiu, K L Choi, C H Choi, Y W Ng, S C Tiu.   

Abstract

OBJECTIVES: To explore the prevalence of various categories of hypertension in diabetic patients, and assess any corresponding associations with end-organ complications.
DESIGN: Cross-sectional study.
SETTING: Tertiary centre of a regional hospital in Hong Kong. PATIENTS: All ambulatory type 2 diabetic patients attending our clinics from January 2002 to November 2004 were invited to participate in the protocol.
RESULTS: A total of 133 diabetic patients were included; 82 had normal clinic blood pressures, 15 (18%) of whom had masked hypertension, the remaining 67 (82%) had 'normotension'. The remaining 51 patients had high clinic blood pressures, of whom 28 (55%) had white-coat hypertension and 23 (45%) had sustained hypertension. Urinary albumin excretion rate was higher in patients with masked hypertension (10 mg/day; range, 7-580 mg/day) and sustained hypertension (7 mg/day; 7-3360 mg/day) in comparison to those with white-coat hypertension (7 mg/day; 7-109 mg/day) or 'normotension' (7 mg/day; 7-181 mg/day) [P<0.01]. Likewise, the prevalence of albuminuria was significantly higher in patients with masked hypertension (40%) and sustained hypertension (26%) than in those with 'normotension' (6%) and white-coat hypertension (11%) [P<0.01]. The prevalence of left ventricular hypertrophy was significantly higher in subjects with masked hypertension (38%) and sustained hypertension (26%) compared to patients with 'normotension' (8%) or white-coat hypertension (11%) [P<0.01]. Left ventricular diastolic dysfunction was more prevalent in patients with masked hypertension (46%), sustained hypertension (48%), and white-coat hypertension (43%) in comparison to subjects with 'normotension' (18%) [P=0.01].
CONCLUSION: Masked hypertension is associated with a higher prevalence of albuminuria, left ventricular diastolic dysfunction, and hypertrophy. White-coat hypertension carries a more benign prognosis than sustained hypertension and masked hypertension. Our cross-sectional study supports the recommendation to performing ambulatory blood pressure measurements in type 2 diabetic patients.

Entities:  

Mesh:

Year:  2008        PMID: 19060342

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  5 in total

Review 1.  Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.

Authors:  Asadur Rahman; Hirofumi Hitomi; Akira Nishiyama
Journal:  Hypertens Res       Date:  2017-01-19       Impact factor: 3.872

Review 2.  Ambulatory blood pressure monitoring in the diagnosis and management of hypertension.

Authors:  Ehud Grossman
Journal:  Diabetes Care       Date:  2013-08       Impact factor: 19.112

Review 3.  Decoding white coat hypertension.

Authors:  Dennis A Bloomfield; Alex Park
Journal:  World J Clin Cases       Date:  2017-03-16       Impact factor: 1.337

4.  Discrepancy between tonometric ambulatory and cuff-based office blood pressure measurements in patients with type 1 diabetes.

Authors:  Simone Theilade; Maria Lajer; Christel Joergensen; Frederik Persson; Peter Rossing
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-03       Impact factor: 3.738

5.  Masked hypertension in diabetes mellitus: treatment implications for clinical practice.

Authors:  Stanley S Franklin; Lutgarde Thijs; Yan Li; Tine W Hansen; José Boggia; Yanping Liu; Kei Asayama; Kristina Björklund-Bodegård; Takayoshi Ohkubo; Jørgen Jeppesen; Christian Torp-Pedersen; Eamon Dolan; Tatiana Kuznetsova; Katarzyna Stolarz-Skrzypek; Valérie Tikhonoff; Sofia Malyutina; Edoardo Casiglia; Yuri Nikitin; Lars Lind; Edgardo Sandoya; Kalina Kawecka-Jaszcz; Jan Filipovsky; Yutaka Imai; Jiguang Wang; Hans Ibsen; Eoin O'Brien; Jan A Staessen
Journal:  Hypertension       Date:  2013-03-11       Impact factor: 10.190

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.